Table S10. Baseline patients' characteristics across SNPs-based prognostic groups

	No high-risk SNPs N=133 (15%)	1 high-risk SNP N=530 (60%)	>1 high-risk SNPs N=223 (25%)	p value
Age (median, IQR)	57 (53-64)	61(54-67)	61 (55-68)	0.002
Ever smoker	29 (21.8)	107 (20.2)	35 (15.7)	0.264
BMI (kg/m^2)				
<24	48 (26.1)	155 (29.2)	84 (37.7)	0.034
≥24	81 (60.9)	365 (68.9)	132 (59.1)	
Missing	4 (<1)	10 (<1)	7 (<1)	
Tumor size				
pT1	77 (57.9)	343 (64.7)	134 (60.1)	0.523
pT2	44 (33.0)	146 (27.5)	73 (32.8)	
pT3-4	7 (<1)	31 (5.8)	12 (<1)	
Missing	5 (<1)	10 (<1)	4 (<1)	
Nodal status				
pN0	65 (48.9)	266 (50.2)	104 (46.6)	0.713
pN1-3	67 (50.4)	258 (48.7)	115 (51.7)	
Missing	1 (<1)	6 (<1)	4 (<1)	
Tumor Grade				
G1	21 (15.8)	96 (18.1)	33 (14.8)	0.467
G2	68 (51.1)	268 (50.6)	130 (58.3)	
G3	29 (21.8)	132 (24.9)	48 (21.5)	
Missing	15 (11.3)	34 (<1)	12 (<1)	
(Neo)adjuvant CT				
No	42 (31.6)	190 (35.8)	72 (32.3)	0.525
Yes	91 (68.4)	340 (64.2)	149 (66.8)	
Missing	0	0	2 (<1)	
Tamoxifen, years (median, IQR)	2.8 (2.2-4.7)	2.7 (2.2-4.9)	2.6 (2.2-4.9)	0.976
Letrozole, years (median, IQR)	3.1 (2.0-5.0)	3.2 (2.4-5.0)	3.2 (2.3-5.0)	0.296